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ABSTRACT 
I. COMPLEXATION OF FE(II), Nl(ll), CU(II) AND ZN(II) BY HEXADENTATE 
TRIPODAL AMINOPYRIDYL CHELATORS. Il.THE POTENTIAL OF CURCUMIN 
IN MEDICINE: SYNTHESIS AND IRON COORDINATION CHEMISTRY OF 
CURCUMINOIDS 
By 
Joon Hyung Cho 
University of New Hampshire, September, 2008 
Chapter 1 
Binding properties of tach-3-MeOpyr with Zn(ll), Cu(ll), Fe(ll) and Ni(ll) 
have been studied and compared to other tachpyr family metal complexes. The 
hypothesis was that weak binding between metals and the tachpyr ligand family 
might be responsible for its lower cytotoxicity towards cells. However, the 
electronic and structural data in solution do not demonstrate any signs of weaker 
binding for Cu(ll), Fe(ll) and Ni(ll) between tach-3-MeOpyr and tach-3-Mepyr. 
While tachpyr, tach-3-Mepyr and tach-3-MeOpyr all have similar binding 
properties toward Fe(ll) in an oxygen free environment, the rates of oxidative 
dehydrogenation of their Fe(ll) complexes in air are substantially different. The 
rate of oxidation of the chelators appears related to their mechanism of 
cytotoxicity because rates of cytotoxicity correlated with the rate of oxidation. 
xv 
Chapter 2 
Two curcumin analogues (2,4-DMCU, 4,4'-DMCU) and curcumin were 
synthesized via Pabon's method with some modification. These two synthetic 
derivatives contain the same metal binding motif with different aryl rings. All 
curcuminoids have shown keto-enol tautomers in solution, characterized by 1H 
and 13C NMR. 
Chapter 3 
Upon deprotonation of the (3-diketone structural motif, curcumin will 
chelate a variety of divalent and trivalent metal ions, Ga(lll), In(lll), Cu(ll), Mn(ll), 
and Fe(lll). Depending on the experimental conditions, UV-Vis 
spectrophotometric titrations showed the formation of iron-curcuminoids 
complexes with M:L stoichiometries of 1:1,1:2 or 1:3. A combination of EPR, 
Evans' method, and spectrophotometric studies indicate that Fe(lll) is reduced to 
Fe(ll) by reaction with curcumin anions under aerobic conditions but not with a 
synthetic derivative 4,4'-dimethoxycurcumin (4,4'-DMCU). Although curcumin 




This thesis is divided into three separate chapters: I) Structure and 
Electronic Properties of Fe(ll), Cu(ll), Ni(ll) and Zn(ll) Complexes of Pyridine-
Ring Alkylated Hexadentate Aminopyridyl Ligands ; II) The Potential of Curcumin 
in Medicine: Synthesis of Curcuminoids; III) Iron Coordination and Redox 
Chemistry of Curcuminoids. Due to two separate topics being covered, each 




STRUCTURE AND ELECTRONIC PROPERTIES OF FE(II), CU(II), Nl(ll) AND 
ZN(II) COMPLEXES OF PYRIDINE-RING ALKYLATED HEXADENTATE 
AMINOPYRIDYL LIGANDS 
Introduction 
Although the medicinal use of metals goes back almost 5000 years,1 
interest in metal chelators for medicinal applications has recently increased 
significantly. Nuclear medicine,2 magnetic resonance shift reagents,3 and 
detoxification of overloaded metal ions4"6 are just a few examples. Understanding 
metals in biology, their coordination chemistry, and their biological activities are 
essential in order to design new and modify existing metal chelators.7 
Iron is an essential cofactor in many vital cellular processes including 
respiration and DNA (deoxyribonucleic acid) synthesis. Rapidly proliferating 
cancer cells require large quantities of deoxyribonucleotides for DNA replication.8 
Deoxyribonucleotide synthesis processes are mediated by the enzyme 
ribonucleotide reductase. Divalent iron is an important cofactor for the catalytic 
activity of this enzyme and must be taken up at a greater rate by cancer cells 
than by normal tissue.9 The intake of iron is mediated by the cellular surface 
receptor for transferrin, and in order to meet the demands of a high rate of cell 
growth and division, cancer cells have an increased number of transferrin 
receptors on their cell surface.9"12 This renders cancer cells more sensitive to 
small fluctuations in bioavailable iron than normal cells.11,13"16 
2 
Several iron chelators have been considered as potential 
chemotherapeutic agents.9'11 Among the candidates are desferrioxamine 
(DFO).5,17 In addition, the novel ligand A/,A/',A/"-tris(2-pyridylmethyl)-c/s> c/s-1,3,5-
triaminocyclohexane (tachpyr) and analogues based on the cis,cis-1,3,5-
triaminocyclohexane (tach) framework have been extensively studied as divalent 
iron chelators capable of selective tumor toxicity.18"22 
HOOC-
N ^ ^COOH H 2 N 2 ^ ^ ^ N H 2 





Scheme 1.1. EDTA (a), tach (b), Desferrioxamine (DFO) (c) 
In vitro addition of tachpyr to MBT2 and T24 bladder cancer cells induced 
apoptosis at very low effective concentrations at IC5o 2.2 uM and 4.3 uM 
respectively.12 As expected, the chelator required a much greater concentration 
to cause similar cytotoxicity in normal cell lines (IC5o=30.5 uM), and was overall 
much more potent than DFO (IC50 = 70 uM with MBT2). Tachpyr has been 
reported to have similar cytotoxic effects in human cervical and breast cancer 
cells.12 Data indicate that the ability of tachpyr to sequester iron is the basis of its 
toxicity, as with DFO.12 The chemical properties of tachpyr, based on its donor 
3 
atoms, sterics, and lipophilicity, is an inherent part of its efficacy as an antitumor 
agent.22 
The c/s,c/'s-1,3,5-triaminocyclohexane (tach) framework is well-suited to 
complexes of first-row dicationic transition-metals of ionic radius 0.75 - 0.88 ,18, 
20-27
 The flexibility of the pyridyl arms allows coordination to various metal ions. 
However, tachpyr complexes of Fe(ll), Cu(ll), and Zn(ll) have been shown to be 
non-toxic in vitro, indicating that the stability of the complex precludes release of 
the free ligand.28 Other divalent metals afford more labile tachpyr complexes and 
are therefore cytotoxic, as the activity of tachpyr is not masked by the metal.28 
The pyridine rings increase the lipophilicity of the molecule, allowing greater 




W ^ tach-3-Rpyr 
R
 R = Me or MeO 
[M(tach-3-Rpyr)]2+ 
Scheme 1.2. Structures of tachpyr: open and closed conformation 
12 Tachpyr shows high cytotoxic effects toward human bladder tumor cells 
No cytotoxic effects were shown from Fe(ll) and Zn(ll) complexes, when various 
metal tachpyr complexes were examined for their cytotoxity. In addition, there 
were no cytotoxic effects of tachpyr when the cells were pretreated with Zn(ll) or 
4 
Fe(ll). These results demonstrate that tachpyr may cause starvation of 
biologically essential metals, such as Fe(ll) and Zn(ll), in cells through metal 
chelation. In fact, preventing iron cellular uptake limits the rapid replication of 
cancer cells, ultimately leading to antiproliferation. 
The Fe(ll) complex [Fe(tachpyr)]CI2 is low-spin, indicative of a strong 
metal-ligand interaction.12'18 The interaction of tachpyr with Fe(ll) in the presence 
of O2 leads to oxidative dehydrogenation of tachpyr, forming tachpyr-imino 
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[Fe(tachpyr-ox-2)] 2+ 
and 








Scheme 1.3. Fe(ll)-mediated oxidation of tachpyr under ambient conditions12 
6 
Various positions on the pyridine substituent of tachpyr (tach-x-Rpyr, x=3, 
4, 5, or 6, R= Me or MeO) have been alkylated and studies of the resulting 
compounds have demonstrated different coordination chemistry and cytotoxicity 
relative to tachpyr.20 (Scheme 1.3.) 
Six-substituted chelators, both tach-6-Mepyr and tach-6-MeOpyr, had 
nearly no toxic effects. This lack of cytotoxicity was caused by weakened 
interactions from steric interactions among the 6-substitutents in metal-bound 
tach-6-Rpyr. Although little difference in ligand-field strength toward 3d divalent 
metals was observed among 3, 4, and 5 positions, tach-3-Mepyr was the most 
interesting due the fact that it killed cells faster than tachpyr.20 
tach-n-Rpyr (n = 3,4, 5, or 6, R = Me or MeO) 
Scheme 1.4. Structures and labeling of tach-n-Rpyr 
Recent cytotoxicity studies of tach-3-MeOpyr have shown that it has much 
lower toxicity than tachpyr and tach-3-Mepyr.19 (Table 1.1) According to IC50 
values (concentrations of the drug needed to inhibit proliferation by 50%), it 
requires longer time and uses higher concentration to be toxic toward the cells 
than tachpyr and tach-3-Mepyr. The chelator tach-6-Mepyr displayed no 
cytotoxicity and was not studied further. At 24 hours tach-3-Mepyr is more toxic 
7 
than tachpyr and significantly more toxic than tach-3-MeOpyr. However, the 
toxicity of tach-3-MeOpyr increases dramatically from 24 hours to 72 hours, as 
expressed by the value AIC50(24 - 72 hours). After 72 hours, it only takes twice 
as much tach-3-MeOpyr as either tach-3-Mepyr or tachpyr to kill half the cells. 
Table 1.1. IC50 values of tachpyr, tach-3-Mepyr, and tach-3-MeOpyr after 24, 48, 





























The overall goal of this research is to identify the chemical properties that 
direct antiproliferative activity of a diversity of chelators that are structurally 
similar to tachpyr. If we understand why these chelators are toxic, i.e., the 
structure-function relationships and mechanism of action, this would be of great 
help in developing them as the ligand-design of chemotherapeutic agents. This 
chapter outlines the progress towards clarifying the coordination chemistry of 




The UV/Vis/NIR spectra was used to measure compound 1 with selected 
divalent metals, Ni(ll), Fe(ll) and Cu(ll), examining these metal-complex 
structures in solution. The results were assigned and compared to [Ni(tach-3-
Mepyr)]2+, [Fe(tach-3-Mepyr)]2+ and [Cu(tach-3-Mepyr)]2\ respectively. (Table 
1.2) 
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The spectrum of [Ni(tach-3-MeOpyr)] shows three d-d transitions as 
seen in [Ni(tach-3-Mepyr)]2+.Three peaks are assigned to the spin-allowed 3A2g 
—•
 3T2g, 3A2g -> 3Tig and a high energy metal-to-ligand charge-transfer (MLCT) 
band. The spin forbidden 3A2g -> 1Eg transition is observed as a lower energy 
shoulder to the 3A2g —> 3T2g transition. Since the 3A2g —• 3T2g is mixing with the 
spin forbidden transition, its energy can only be approximated. 
There was a notable difference in UV/Vis/NIR spectra between [Cu(tach-
3-Mepyr)]2+ and [Cu(tach-3-MeOpyr)]2+. [Cu(tach-3-Mepyr)]2+ shows a single 
broad absorption at 15,300 cm"1, which suggests tetragonally distorted six-
coordinated Cu(ll). However, [Cu(tach-3-MeOpyr)]2+ shows one broad peak at 
15,300 cm"1 with a shoulder at 10941 cm"1, suggesting that [Cu(tach-3-
MeOpyr)]2+ has square pyramidal five-coordination29 as seen by Matt Childers for 
[Cu(tach-6-Mepyr)]2+ and [Cu(tach-6-MeOpyr)]2+.27 This was supported by 
deconvoluting the broad peak and shoulder which gave three bands assigned to 
the dz2 -» dx2.y2, dxy -» dx2-y2, and dxziyz-» dx2.y2 transitions in order of increasing 
energy.29 This assignment of d-d transition on a square pyramidal Cu(ll) complex 
is given as transitions between individual orbitals according to literature 
conventions.20'22,26'27,29 In summary, the UV/Vis/NIR measurements of [Ni(tach-
3-MeOpyr)]CI2 and [Cu(tach-3-MeOpyr)](CI04)2 indicate 6-coordinated Ni(ll) and 
5-coordinated Cu(ll) in solution. 
The electronic spectrum of [Fe(tach-3-MeOpyr]2+ is dominated by a metal-
to-ligand charge-transfer (MLCT) band at 23,000 cm-1 (c = 6500 M"1 cm"1) with a 
low-energy shoulder at 18,800 cm"1 (e = 350 M"1 cm-1), quite similar to that of 
10 
[Fe(tach-3-Mepyr)r , whose MLCT band appears at 22,700 cm"1 
(e = 7000 M"1 cm"1) and shoulder at 18,200 cm"1 (e = 290 M"1 cm"1). The low-




1H NMR spectra of [Zn(tach-3-MeOpyr)]2+ was compared to the free ligand 
of tach-3-MeOpyr to gain more information about the nature of the metal complex 
in solution. Upon complexation with Zn(ll), the equatorial arms of the free ligand 
coordinate with Zn(ll) and assume the axial position due to a chair-chair flip 
conformation. The change in 1H NMR spectra is due to the relative positions of 
cyclohexyl ring protons Ha, Hb, and Hc. (Scheme 1.5.) The splitting patterns of 
these free ligand ring protons are shown in Table 1.3. 
Table 1.3. The change in 1H NMR spectra due to the relative positions of 
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Scheme 1.5. Free ligand (open conformation) and metal complex (closed 
conformation) 
13 
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Figure 1.1.1H NMR spectra of tach-3-MeO and [Zn(tach-3-MeOpyr]2+ in d-
DMSO 
The 1H NMR spectrum of [Fe(tach-3-MeOpyr]2+ indicates a diamagnetic, 
low-spin-state of Fe(ll). Upon complexation with Fe(ll), the equatorial arms of the 
free ligand coordinate with Fe(ll) and assume the axial position due to a chair-
chair flip conformation. 
Relative Rates of Oxidation for Tach-3-MeOpyr Fe(ll) Complexes 
The combination of ligand with Fe(ll) in the presence of air (O2) leads to 
oxidative dehydrogenation of ligand, forming tachpyr-imine derivatives of Fe(ll) in 
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D20. (Figure 1.2) The 1H NMR was used for quantitation using the signals of the 
imino protons, -N=CH-, which appear as a singlet in the range of 9.2 - 9.6 ppm 
for the derived monoimino complexes and as a doublet in the range of 8.8 - 9.2 
ppm for the diimino complexes from [Fe(tach-3-Mepyr]2+, [Fe(tach-3-MeOpyr]2+, 




Figure 1.2. The oxidative dehydrogenation process of [Fe(tach-3-MeOpyr]2+ in 
D2O to after 4 hours and 24 hours 
X-ray Crystallography 
To obtain further chelator structural parameters that may underlie optimal 
Fe(ll) binding, the X-ray structure was determined as the salts [Fe(tach-3-
MeOpyr)](FeCl4). The solid state data gave the average Fe-Npy and Fe-Namine 
bond lengths for [Fe(tach-3-MeOpyr)](FeCI4) were 1.975 ' and 2.012 ' 
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respectively. The Fe complex possess a trigonally distorted octahedral 
coordination geometry, as indicated by its trigonal twist angles (4s) 54.6°, 
compared to a P of 60° for a perfect octahedron. Twist angle is defined the angle 
through which one face of an octahedron has been rotated with respect to the 
opposite face, as viewed along a threefold axis of the octahedron. (Figure 1.3) 
The average Np^Fe-Namine angle of the 5-membered chelate rings (a) is 
84.0°, which is comparable to other Low-Spin (LS) aminomethylpyridyl iron 
complexes as seen in the [Fe(tptcn)]2+ and /ac-[Fe(ampy)3]2+. 
Table 1.4. Structural data for [Fe(tach-3-MeOpyr)] and comparisons to other 



































































Figure 1.3. Structure of [Fe(tach-3-MeOpyr)] (top view) and the Definition of 
Twist Angles using metal tachpyr complex 
Figure 1.4. Structure of the complex cation of [Fe(tach-3-MeOpyr)](FeCl4) 
(ORTEP; 50% probability ellipsoids) showing the atom-numbering scheme. 
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Solid-state structural data was obtained for Cu(ll) complex using X-ray 
crystallography. The average Cu-N(py) and Cu-N(amine) bond lengths are 2.147 
A and 2.120 A respectively. The twist angle of 47.2 ° indicates a trigonally 
distorted octahedral coordination geometry. 


































The geometry of Cu(ll) complex shows an elongated tetragonal 
octahedron due to a Jahn-Teller distortion. Two trans nitrogen donors, N(3) from 
tach and N(5) from pyridyl, bind weakly to Cu(ll) affording longer Cu-N bond 
distances of 2.350(5) A and 2.220(5) A, respectively. (Table 1.5) 
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C4 C2 
Figure 1.5. Structure of the complex cation of [Cu(tach-3-MeOpyr)] 
Gas Phase Studies 
Electrospray ionization mass spectrometry (ESI-MS) was used to verify 
metal complexation (zinc, copper, nickel) with tach-3-MeOpyr. This is a relatively 
soft ionization technique that can produce multiple charged ions from a solution. 
One of the strengths of this method over the fast atom bombardment (FAB-MS) 
method is that the solution composed of a volatile solvent and ionic analyte 
require only very low concentrations.30 
In recent years, there has been an increase in the use of ESI-MS for 
coordination chemistry in gas-phase.30"34 Although there is uncertainty 
concerning the mechanisms of ESI process, it is understood that it produces gas-
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phase ions directly from a solution.30 This ability to analyze species in the 
solution phase allows us to make gas-phase studies of tach-3-MeOpyr with Cu(ll), 
Zn(ll), and Ni(ll) in methanol. 
Solutions containing [M(tach-3-MeOpyr)](CI04)2 were prepared over a 
range of sample concentrations from 10"4 to 10"6 M in methanol, where M is Zn(ll), 
Ni(ll), or Cu(ll). [Fe(tach-3-MeOpyr)]CI2 and [Fe(tach-6-Mepyr)]CI2 were also 
studied under similar conditions. There was no evidence of any solvent 
coordination in any metal complexes. 
i 
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Figure 1.6. An example of the electrospray mass spectrum: [Zn(tach-3-
MeOpyr)](CI04)2 - a cluster of peaks at m/e = 555.4 with a simulated peak of 
proposed species using an ISI MS simulating tool. 
The electrospray mass spectrum of [Zn(tach-3-MeOpyr)](CI04)2 was 
obtained in methanol solution. The highest intensity occurred at a cluster of 
dicationic peaks at m/e(mass/charge) = 278.4, corresponding to "[M(tach-3-
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MeOpyr)](CI04)2 - 2(CI04")", followed by a cluster of monocationic peaks at m/z = 
555.4, "[M(tach-3-MeOpyr)](CI04)2 - 2(CI04") - H+", of slightly less intensity. 
Table 1.6. m/z values, calculated compounds, and proposed species of the 
characteristic metal-containing peaks in the ESI mass spectra of [Zn(tach-3-













A - CICV 
A - 2(CI04") - H+ 
A - 2(CI04") - C7H8ON2 
A - 2(CI04") 
For [Ni(tach-3-MeOpyr)](CI04)2, a cluster of peaks was observed at m/e = 
275.4, which corresponds to dication "[M(tach-3-MeOpyr)](CI04)2 - 2(CI04")", and 
had the highest intensity at nearly 90%. (Table 1.7) 
Table 1.7. m/z values, calculated compounds, and proposed species of the 
characteristic metal-containing peaks in the ESI mass spectra of [Ni(tach-3-












B = [Ni(tach-3-MeOpyr)](CI04)2 
B - CICV 
B - 2 ( C I 0 4 ) - H+ 
B - 2(CI04-) - C7H8ON2 
B - 2(CI04-) 
In the case of [Cu(tach-3-MeOpyr)](CI04)2, the highest intensity was 
observed by a cluster of peaks at m/e = 554.2, which corresponds to "[M(tach-3-
MeOpyr)](CI04)2 - 2(CI04") - H+". Other clusters of peaks are shown in Table 1.8. 
The most notable peak from Cu(ll) was a cluster of peaks at m/e = 432.3. This 
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corresponds to the species, "[M(tach-3-MeOpyr)](CI04)2 - 2(CI04") - C7H8ON", 
which was not found in the Ni(ll) and Zn(ll) complexes. 
Table 1.8. m/z values, calculated compounds and proposed species of the 
characteristic metal-containing peaks in the ESI mass spectra of [Cu(tach-3-














C = [Cu(tach-3-MeOpyr)](CI04)2 
c - cio4-
C - 2 ( C I 0 4 ) - H+ 
C - 2(CI04") - C7H8ON 
C - 2(CI04") - C7H8ON2 
C - 2(CI04") 
The electrospray mass spectrum of [Fe(tach-3-MeOpyr)]CI2 was obtained 
in a methanolic solution. The highest intensity occurred at a cluster of dicationic 
peaks at m/e = 272, corresponding to "[Fe(tach-3-MeOpyr-ox-4]2+", followed by a 
cluster of peaks at m/e = 543, "[Fe(tach-3-MeOpyr-ox-4]2+ - H+", of less intensity. 
As determined by NMR analysis, imine species are observed to oxidativly-
dehydrogenate in the presence of air. During ESI-MS experiments, traces of 
unoxidized and monoimine species have been observed. 







274 (z = +2) 
547 (z = +1) 
273 (z = +2) 
5 4 5 ( Z = + 1 ) 
272 (z = +2) 
543(z = +1) 
278 (z = +2) 









The electrospray mass spectrum of [Fe(tach-6-Mepyr)]Cl2 in methanol 
solution does not show any oxidativly-dehydrogenated species. The highest 
intensity occurred at a cluster of peaks at m/e = 250, corresponding to "[Fe(tach-
6-Mepyr]2+", followed by a cluster of peaks at m/e = 499, "[Fe(tach-6-Mepyr]2+ -
H+", of less intensity.) 
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 Confirmation of all major species in this ESI-MS study was aided by comparison 
of the observed and predicted isotope distribution patterns from the program, 
ISOFORM ver. 1.02, developed by NIST. 
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Discussion 
The influence of tach-3-MeOpyr to tach-3-Mepyr on the electronic 
structures of nickel, iron and copper complexes was examined by UV/Vis/NIR 
spectra. Comparison of [Ni(tach-3-Mepyr)](CIC>4)2 and [Ni(tach-3-MeOpyr)]Cl2 
does not suggest any significant differences between approximated A0 at 12600 
cm"1 and 12700 cm"1, respectively. 
The electronic spectrum of [Fe(tach-3-MeOpyr]2+ is dominated by a metal-
to-ligand charge-transfer (MLCT) band at 23 000 cm-1 (e = 6500 M"1 cm"1) and 
with a low-energy shoulder of a d-d band at 18 800 cm -1 {E = 350 M"1 cm"1), 
quite similar to that of [Fe(tach-3-Mepyr)]2+ whose MLCT band appears at 
22 700 cm"1 (e = 7000 M"1 cm"1) and shoulder at 18 200 cm"1 (e = 290 M"1 cm"1). 
Consistent with Ni(ll) complexes, no significant differences were found between 
two Fe(ll) complexes. 
Results of the Fe(ll) complex in the presence of oxygen leads to oxidative 
dehydrogenation of tach-3-MeOpyr, forming tach-3-MeOpyr-imino derivatives, 
such as [Fe(tach-3-MeOpyr-ox-2)]2+ and [Fe(tach-3-MeOpyr-ox-4)]2+, as 
confirmed with UV/Vis/NIR and ESI-MS spectra. 
The UV/Vis/NIR spectrum of [Cu(tach-3-MeOpyr)]2+ presents a lower 
energy shoulder which is a diagnostic sign of five-coordination as seen for 
[Cu(tach-6-Xpyr)]2+, (X = Me or MeO.) There are two known geometries for the 
complexes, trigonal bipyramidal (D3h) and square pyramidal (C4v)- (Figure 1.7) 
One distinction is the number of absorption peaks presented; two for D3h and 
three for C4v. Another diagnostic tool indication is the location of the shoulder 
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absorption peak. The D3h complex will have a shoulder on the high energy side of 
the main peak, whereas the C4V complex will have a shoulder on the low energy 
side relative to the main peak. Three Gaussian peaks were evident from further 
spectral analysis of [Cu(tach-3-MeOpyr)]2+, using Origin software. (Figure 1.8) 
2 2 These were assigned to the dz —• dx .y , dxy —> dx -y , and dxziyz—• dx -y 
transitions in order of increasing energy. It is well known that the solution spectra 
of Cu(ll) complexes can be difficult to measure because they are likely to have 
multiple overlapping peaks. However, this Cu(ll) spectrum is very similar to other 
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Figure 1.8. Electronic spectrum of [Cu(tach-3-MeOpyr)] 
The ESI-MS spectra complement the data obtained from solution 
UV/Vis/NIR studies. Analysis of the electrospray mass spectra of [Zn(tach-3-
MeOpyr)](CIC>4)2 and [Ni(tach-3-MeOpyr)](CIC>4)2 reveal that there are similar 
patterns of fragment loss. For example, there were losses of "[M(tach-3-
MeOpyr)](CI04)2-2(CI04')-H+" and "[M(tach-3-MeOpyr)](CI04)2-2(CI04")", with 
relatively high intensity. Also, there were losses of "[M(tach-3-MeOpyr)](CI04)2-
2(CI04")-C7H8ON2" from both zinc and nickel complexes. (Figure 1.9) However 
there was no indication of metal loss from each complex as no free tach-3-
MeOpyr was indicated, which indicates strong binding between metal and ligand. 
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Figure 1.9. Possible location of fragmentations for [Zn(tach-3-MeOpyr)](CI04)2 






The loss of this 
fragment(C7H8ON2) 
results in a peak at 
419.3 m/z. 
Similar patterns were observed for [Cu(tach-3-MeOpyr)](CI04)2 except for 
a cluster of peaks at m/e = 432.2, which is a loss of C7H8ON, a pendant arm 
without the amino-nitrogen. This fragment pattern is similar to that of one recent 
study of [Cu(TPEN)](PF6)2, which demonstrates 5-coordinated Cu(ll) in the solid-
phase, solution, and the gas-phase.35 The hexadentate ligand, A/./V./V./V-
tetrakis(2-pyridylmethyl)ethlenediamine (TPEN), provides valuable data as a 
model for tachpyr and its derivatives, because both ligands are similar in 
composition (hexadentate N-donors). This gives evidence that the pyridine 
component of the pendant arm is not bound with Cu(ll), creating a 5-coordinated 
complex instead of a 6-coordinated one.(Figure 1.10) Therefore, the ESI-MS 
data of [Cu(tach-3-MeOpyr)](CI04)2 suggests 5-coordinated Cu(ll) in gas-phase. 
This conclusion is not surprising due to the fact that Cu(ll) is well known for its 
flexible coordination spheres. 
From structural studies, the Fe(ll) complex shows a trigonally distorted 
octahedral coordination geometry. As observed in [Fe(tach-3-MeOpyr)]2+, the Fe-
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N(py) bonds are generally shorter than the Fe-N(amine) bonds due to dTT -> pTT* 
backbonding of Fe(ll) to the ligand when low-spin Fe(ll) complexes contain the 
aminomethyl pyridyl binding group. The large twist angle of 54.6 ° can be 
attributed to the large LFSE of an octahedral LS Fe(ll) geometry. 
Cu(ll) complex shows an elongated tetragonal octahedron due to the 
Jahn-Teller effect. Its Cu-N(amine) and Cu-N(py) bond lengths are in good 
agreement with other Jahn-Teller Cu(ll) complexes. 
Figure 1.10. Possible locations of fragmentations for [Cu(tach-3-








The loss of this 
fragment(C7H8ON) 
results in a peak at 432.3 
m/z. 
The loss of this 
fragment(C7H8ON2) 
results in a peak at 418.3 
m/z. 
28 
Relative Rate of Oxidation of Tachpyr and Derivatives 
In our previous studies, it has been shown that under aerobic conditions, 
tachpyr Fe(ll) complexes undergo an iron-mediated oxidative dehydrogenation 
giving [Fe(tachpyr-monoimne)]2+ and [Fe(tachpyr-diimine)]2+ complexes, as 
shown in Scheme 1.3. H2O2 is required to generate the trisimine complex, 
[Fe(tachpyr-trisimine)]2+. This reaction has at least two significant effects to 
tachpyr-family chemistry and biology. First, the redox process may generate 
reactive oxygen species that can cause cellular injury and death. Second, TT-
backbonding is greater to the iminopyridyl group than to the aminopyridyl group, 
affording stronger binding of Fe(ll). Therefore, even though Zn(ll) can compete 
favorably with Fe(ll) for the tachpyr family under anaerobic conditions, the 
chelator binds increasing amounts of iron relative to zinc, as the oxidative 
dehydrogenation progresses. 
The [Fe(tach-x-Mepyr)]2+ species (x = 3, 4, or 5) have been extensively 
studied. While there is no substantial difference in ligand-field strength of 
tachpyr-family ligands, alkylation at the 3, 4, or 5 position of the pyridine rings of 
tachpyr change the rate of oxidation of the Fe(ll) complexes. The rate is 
substantially accelerated with 3-methylation. Therefore, it was of great interest to 
pursue further substitutions at the 3-position of the tachpyr chelator to study 
oxidative dehydrogenation of Fe complexes. 
The oxidative dehydrogenation of Fe complexes of tachpyr, tach-3-Mepyr, 
and tach-3-MeOpyr was followed by 1H NMR in D2O with co-worker, Matt 
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Childers. The relative rates were calculated by comparing the integrations of the 
monoimine signals (9.2 - 9.6 ppm) to the integration of the aromatic peaks. 
Table 1.11. Ratio of area under monoimine peak of Fe(ll) complexes to the area 


















The relative rate of [Fe(tach-3-Mepyr)]2+ oxidation by 1H NMR was the 
fastest, followed by [Fe(tachpyr)]2+ and [Fe(tach-3-MeOpyr)]2+. [Fe(tach-6-
Mepyr)]2+ does not undergo iron-mediated oxidative hydrogenation and does not 
kill cells. While the underlying biological and chemical reasons are not yet 
understood, the rates of iron-mediated oxidative dehydrogenation follow same 
order of rates of cell-killing. (Table 1.12) 
Table 1.12. IC50 values (uM) of tachpyr, tach-3-Mepyr, tach-3-MeOpyr, and tach-
6-Mepyr after 24, 48 and 72 hours with the relative rates of oxidation of the Fe(ll) 






























No oxidized products 
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Conclusion 
Binding properties of tach-3-MeOpyr with Zn(ll), Cu(ll), Fe(ll) and Ni(ll) 
have been studied and compared to other tachpyr family metal complexes. The 
hypothesis was that weak binding between metal and the ligand might be 
responsible for its lower cytotoxicity towards cells. However, the electronic and 
structural data in solution do not demonstrate any signs of weaker binding for 
Cu(ll), Fe(ll) and Ni(ll) between tach-3-MeOpyr and tach-3-Mepyr, so the 
hypothesis could not be confirmed. 
While tachpyr, tach-3-Mepyr and tach-3-MeOpyr all have similar binding 
properties toward Fe(ll) in an oxygen free environment, the rates of oxidative 
dehydrogenation of their Fe(ll) complexes in air are substantially different. These 
findings might be rationalized by the need for a greater degree of imine formation 
in order to retain bound iron. Thus, a chelator with slower iron-mediated oxidative 
dehydrogenation such as tach-3-MeOpyr does not convert to the inert [Fe(tach-3-
MeOpyr-monoimine)]2+ form as quickly, thus it takes longer to sequester iron 
inertly. Some connections between the chemistry and biology of tachpyr family 
have been evaluated, but a full understanding of both chemical and biological 
aspects requires further study. 
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CHAPTER II 
THE POTENTIAL OF CURCUMIN IN MEDICINE: SYNTHESIS OF 
CURCUMINOIDS 
Introduction 
Understanding the fundamental coordination chemistry of curcumin in vitro 
could explain some of its remarkable biological effects, such as antitumor activity, 
which are potentially caused by metal participants (e.g. Fenton Chemistry.) This 
chapter describes the synthesis of curcumin, and two of its analogues in 
anticipation of understanding the metal coordination activity described in Chapter 
3. 
Drug Discovery from Natural Products 
Recently, natural products have been major sources of new drugs.36 In 
fact, approximately one-third of the top-selling drugs worldwide are made from 
natural products or their derivatives, and they often find their origins in folk 
medicines.37 The prevailing approach to drug discovery from natural products 
takes advantage of modern high-throughput screening bioassay techniques.38"41 
Using bioactivity-guided fractionation (BGF), crude plant solvent fractions are 
examined for targeted bioactivity, and the fractions are further studied and tested 
for activity until the active pure natural products are isolated and identified. These 
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isolates lead to substances which are synthetically modified to elucidate the 
structure-activity relationships (SARs) and other drug-related properties. 
Optimized drug candidates are designed and developed based on these SARs 
correlations.36'37'40 
Health Benefits of Curcumin 
Curcumin is the major constituent of the yellow pigments isolated from 
Curcuma longa and other Curcuma species. The main components of turmeric 
(Figure 2.1.) include curcumin (77%), demethoxycurcumin (17%), and 
bisdemethoxycurcumin (3%), together referred to as curcuminoids.42,43 
It has been used for centuries in a variety of pharmaceutical applications 
44-46
 including treatment for arthritis47, as an anti-inflammatory agent48"51 and as 
an orally-available treatment for diabetes.52 Recently, turmeric has been found to 
have anticancer, chemopreventive, and hepatoprotective effects.53 
Among all its benefits, our particular interest has focused on curcumin's 
antitumor effects and its potential utility as a cancer chemopreventive agent.54 
Curcumin has been shown to inhibit tumor formation in the skin, forestomach, 
duodenum, and colon in mice.55 Likewise, it has inhibited tumor formation in the 
mammary glands, colon, tongue, and sebaceous glands of rats.56 
These results have led to several clinical trials exploring the utility of 
curcumin as a cancer chemopreventive agent in humans.45 Indeed, Phase I 
clinical trials have demonstrated that curcumin is exceptionally well tolerated 57,58 
and it has been recommended for further evaluation in Phase II trials.57'58 
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Acidity and Tautomerism 
Curcumin is an orange-yellow solid that is bright yellow in organic solvent. 
The color of curcumin stems from its structure, which contains a high degree of 
conjugation extending over all seven carbons that connect the two aryl rings. 
Curcumin possesses three protons that are ionizable in water: the enolic proton 
whose pKa is measured at approximately 8.38 and two phenolic protons whose 
pKa's are placed at 9.88 to 10.51 (in mixed alcoholic/water solvent).59 
o o 
H.co 
Figure 2.1. Structure of Curcuminoids (Beta-Diketone Tautomers); A=curcumin, 
B=demethoxycurcumin, C=bisdemethoxycurcumin 
Although the systematic name for curcumin, 1,7-bis(4-hydroxy-3-
methoxyphenyl)-1,6-heptadiene-3,5-dione, implies that curcumin is a beta-
diketone tautomer (Figure 2.1), X-ray crystal structure analyses have established 
that curcumin and its bisacetoxy derivative exist as keto-enol tautomers in the 
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Figure 2.2. Equilibrating Keto-Enol Tautomers of Curcumin 
Jovanovic et al. noted that the keto-enol-enolate equilibrium of the 
heptadienone moiety of curcumin will determine its physicochemical and 
antioxidant properties, because hydrogen-atom transfer plays a crucial role in 
such actions of curcumin. Additionally the beta-diketone tautomer of curcumin is 
likely to predominate in slightly acidic aqueous solutions in the interior of cell 
membranes.6162 
Stability and Pharmacology 
The stability of curcumin toward chemical degradation in basic conditions 
has been investigated. Tonnesen et al. identified degradation products including 
ferulic acid and feruloylmethane.63 Wang et al. found that curcumin was 90% 
decomposed within 30 minutes in 0.1 M phosphate buffer at pH 7.2 / 37 °C and 
tentatively identified the decomposition product trans-6-(4'-hydroxy-3'-
methoxyphenyl)-2,4-dioxo-5-hexenal, from which they identified vanillin as a final 
product along with ferulic acid and feruloylmethane.64 Stability in cell culture 
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medium containing 10% fetal calf serum or in human blood was greater, but 50% 
of curcumin had still decomposed after 8 hours. Curcumin is also 
photodegradable.63'65 
A number of studies of pharmacology and metabolites of curcumin exist.58, 
64,66-68 j n e j n t e s t j n a | metabolites in human and rats have been identified as 
curcumin glucuronide, curcumin sulfate, tetrahydrocurcumin, and 
hexahydrocurcumin.58,68 Thus, both metabolic conjugation and reduction are 
observed. 68 
Curcumin as an Iron Chelator in vivo and in vitro 
As curcumin is among the more successful chemopreventive compounds 
investigated in recent years,45 it is currently in human trials to prevent cancer.57 
However, the mechanism of action of curcumin is complex and likely multifactoral 
45,69,70 Qu r co||aborators at Wake Forest University have been examining 
curcumin's mechanism of action for chemoprevention, and they have observed 
that curcumin can act as both an iron chelator and antioxidant enzyme inducer 
within the cell.54 
Ferritin, the major iron storage protein, plays a key role in maintaining iron 
homeostasis by capturing and buffering the intracellular labile iron pool.10,71,72 
Levels of ferritin are regulated both transcriptionally by oxidants and cytokines 
and post-transcriptionally by the labile iron in cells. When cellular iron content is 
high, iron regulatory proteins (IRPs - mRNA binding ferritin repressor proteins) 
are deactivated and ferritin translation is increased.10 Previous studies have 
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noted that the synthetic chemopreventive agent, oltripraz, induced ferrtin mRNA 
in concert with other proteins involved in the antioxidant response pathway.71 
However, the effect exhibited by curcumin was an unprecedented dissociation 
between the mRNA and protein regulation.54 Also as ferritin mRNA increased (an 
effect associated with the electrophilic or antioxidant response) the amount of 
ferritin decreased.54 It is known that iron chelators bind intracellular iron and 
activate ferritin translational repressors that repress ferritin at the translational 
level.10'72 Therefore, curcumin is acting as both an iron chelator and antioxidant 
enzyme inducer within the cell. 
Synthesis of Curcumin and Derivatives 
It is our interest to synthesize the curcumin analogues with no phenolic 
hydroxyl groups in order to examine coordination chemistry in vitro. 
Many health benefits have been claimed for curcumin45'53 and they have 
generally been ascribed to its radical-trapping antioxidant properties.53 Since 
curcumin is a bisphenol, its reported ability to trap lipid peroxyl73'74 and 1,1-
diphenyl-2-picrylhydrazyl (DPPH) radicals by donating one of its phenolic H-
atoms 61 is consistent with the known mechanism by which other phenols trap 
peroxyls,75 alkoxyls,76 and DPPH-.76'77 
Curcumin has a relatively simple structure as typical natural products are 
usually more complex. It contains two phenolic rings separated by an 
unsaturated seven carbon chain containing two carbonyls. Curcumin was first 
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synthesized in 1913, by Lampe and Milobedzka in a lengthy and impractical 
eight-step procedure.78,79 
In 1964, curcumin was synthesized in a single step by Pabon.80 Curcumin 
is still synthesized by Pabon's method, despite Babu and Rajaskharan's attempt 
at improving it.36,49'59,81"87 The method of Pabon starts with 2,4-pentanedione 
(acacH) as the central portion of curcumin. In order to avoid the Knoevenagel 
condensation of the central carbon of acacH with a benzaldehyde, the reaction of 
the central carbon is blocked with boron oxide in Pabon synthesis.80 This forces 
terminal CH3 of acacH into the condensation with the substituted benzaldehyde. 
O O 
H H 










Scheme 2.1. An example of Knoevenagel condensation 
38 
O O B20 : , 2 W 3 C k . O 
Bv BO, + HoO 













Repeat Steps # 2 - 4 
three times 
Scheme 2.3. Mechanism of the aldol condensation 
The standard procedure involves the reaction of 2,4-pentanedione, boric 
anhydride, tributyl borate, butylamine, and a substituted benzaldehyde in ethyl 
acetate. In the case of curcumin the substituted benzaldehyde is 4-hydroxy-3-
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methoxybenzaldehyde (vanillin). Pabon used tributyl borate in the reaction but 
does not involve tributyl borate in his proposed mechanism.80 Hydrolysis of the 
proposed boron/curcumin intermediate by warm dilute hydrochloric acid leads to 
curcumin as shown in Scheme 2.4. 
Scheme 2.4. Hydrolysis of the intermediate 
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Results and Discussion 
The target curcumin analogues of this project were to contain the same 
conjugated carbons as in curcumin, but with different substituent in various 
positions on the aryl rings. All of the analogues are symmetrical and the 
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Figure 2.3. DMCU(A) and 2,4-DMCU(B) 
As discussed in the background of this chapter, Pabon has successfully 




O O H3CO OCH3 
i. a) 0.7 equiv B203, EtOAc 
b) 2.0 equiv vanillin, 2.0 equiv B(OiPr)3, EtOAc 
c) 1.5 equiv TEA, EtOAc, dropwise addition over 20 min 
d)1.2N HCI 
Scheme 2.5. The preparation of curcumin: See Table 2.1. for specific reaction 
conditions for the synthesis 
The preparation of curcumin and 4,4'-dimethoxycurcumin (4,4'DMCU), 
employing a procedure based on Pabon's synthesis, gave yields of 73.9 % and 
80.6 %, respectively. However, when similar conditions were used to prepare 
2,4-DMCU, the yield was significantly less, only 20 %. Therefore, conditions were 
modified by substituting piperidine as the base and using higher temperatures 
(100 °C). This modified method improved the yield to 72.5 %. (Table 2.1.) 
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The formation of the ligands (curcumin, 4,4'-DMCU and 2,4-DMCU) was 
verified by 1H NMR, using appearance of a pair of doublets in the aromatic region 
with J values of 15.5 -16.0 Hz for the frans-alkene protons present. (Figure 2.5.) 
Also observed in the 1H NMR was the loss of a signal at -10 ppm for the 
aldehyde proton in the vanillin and the loss of signals at 1.89 ppm and 2.08 ppm 
for the methyl protons on acacH. The structure was also verified using 13C NMR 
by observing the appearance of a signal at -182 ppm for the keto-enol carbonyl 
carbon and the loss of a signal at -195 ppm for the aldehyde carbon in vanillin. 
Also absent from the 13C NMR were signals at 24.1 ppm and 30.2 ppm for the 
methyl carbons in acacH. 
During characterization, the solubility of the ligands was examined for 
concentrations of ca.10 mM. Only DMSO seemed to be a viable solvent for 
curcumin, while two other derivatives dissolved in a wider range of solvents 
(DMF, DMSO/MeOH, DMSO/EtOH, Diethyl ether, isopropyl ether.) Poor aqueous 
solubility on curcumin has been reported (~ 20 ug/mL). 88 






391.2 (Na+ + curcumin) 
419.2 (Na++ 4,4'-DMCU) 






























































8.0 7.9 7.8 7.7 7.6 7.5 7.4 7.3 7.2 7.1 7.0 6.9 6.8 6.7 6.6 6.5 6.4 6.3 6.2 6.1 6.0 5.9 5.8 5.7 5.6 5.5 
f l (ppm) 















| ' r 
-1 
:J J J 
. . r 
Jw ^L_ 
...J \ ±JZ 
4 ! 


































- [ - , 
— 
1 
. ^ | 
—— 
-H 







8.0 7.9 7.8 7.7 7.6 7.5 7.4 7.3 7.2 7.1 7.0 6.9 6.8 6.7 6.6 6.5 6.4 6.3 6.2 6.1 6.0 5.9 5.8 5.7 
f l (ppm) 
Figure 2.5. Selected regions (5.5 to 8.0 ppm) of 1H NMR of 4,4'-DMCU in d-
CDCI3 
Conclusion 
In summary, two curcumin analogues and curcumin were synthesized via 
Pabon's method with some modification. These two synthetic derivatives contain 
the same metal binding motif with different aryl rings. All curcuminoids have 
demonstrated keto-enol tautomers in solution, characterized by 1H and 13C NMR. 
Solubility of curcumin was significantly limited with exception of DMSO among 
the solvents tested. 
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CHAPTER III 
IRON COORDINATION AND REDOX CHEMISTRY OF CURCUMINOIDS 
Introduction 
As mentioned in the previous chapter, it has been shown that curcumin 
acts as an iron chelator in vivo. Our interest, as inorganic chemists, is 
understanding the fundamental coordination chemistry of curcumin and its 
synthetic derivatives, with a particular emphasis on iron in vitro. It is our hope that 
these studies can aid in explaining some of the previously mentioned biological 
effects. 
Metal Binding Properties of Curcumin 
Two potential metal binding sites are available to curcumin. One is the (3-
diketone moiety, and the other is the phenolic 3-methoxy-4-hydroxy site. Due to 
the steric accessibility and the quasi-aromatic nature of the resulting chelate ring, 
the p-diketone is the thermodynamically preferred site of metal binding. (Figure 
3_ 1 _ ) 89,90 
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Figure 3.1. Two potential binding sites of curcumin (A: p-diketone moiety; shown 
as keto-enol tautomers, B: catecholic 3-methoxy-4-hydroxy site) 
Recent Advances on Coordination Chemistry of Curcumin 
Several metal curcumin complexes have been synthesized, characterized 
and evaluated for various biological activities. Upon deprotonation of the p-
diketone structural motif, curcumin will chelate a variety of divalent and trivalent 
metal ions including Fe(lll)90, Cu(ll)91, Ga(lll)89, In(lll)89, Au(l)92, V02 + 93 and 
Mn(ll)94. 
Anti-arthritic properties of a five coordinate curcumin gold complex, 
Au(curcumin)2CI, were assessed in an adjuvant-induced rat polyarthritis model.92 
After three weeks of Au(curcumin)2CI, 30 mg/kg per day by injection, there was 
greatly reduced paw swelling observed.92 
In 2003, two manganese complexes with curcumin and diacetylcurcumin 
were evaluated for in vitro antioxidant properties and superoxide dismutase 
activity with IC50 values for the former in the range 6.3-26.3 uM.94 All the 
complexes were also tested in vivo for their potential as neuroprotective agents 
in vascular dementia. Mn(curcumin)(OAc) showed significant protective effects in 




Figure 3.2. Diacetylcurcumin 94 
The Orvig group at the University of British Columbia has investigated the 
glucose-lowering capabilities and anticancer potential of the individual 
components of commercial curcumin and their associated vanadyl complexes.93 
They were also interested in evaluating the therapeutic potential of gallium and 
indium complexes with curcumin. 89 
Vanadyl curcumin [VO(curcumin)2] was synthesized and characterized by 
the Orvig group in 2004.93 It was more effective as an anti-cancer agent and as 
an inhibitor of synoviocyte proliferation, compared to uncomplexed curcumin or 
vanadyl ion alone. It also proved to be exceptionally non-toxic in vivo, with no 
evidence of negative symptomatology during a month-long treatment period, at 
doses up to and including 2.0 mmol kg"1 d"1.93 
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HO v v OH 
Figure 3.3. Proposed structure of Vanadyl curcumin by the Orvig group 93 
Ga(curcumin)3 and ln(curcumin)3 were prepared in anticipation of 
synergistic effects of curcumin and gallium or indium.89 The interests in gallium 
and indium are as components of medicinal inorganic therapeutic and diagnostic 
agents.95,96 In fact, gallium was the second metal, after platinum, to be used in 
cancer treatment.89'97 Both Ga(lll) and In(lll) curcumin complexes had lower 
cytotoxicity in mouse lymphoma than curcumin alone. Also, comparison of 
antioxidant potential among the complexes indicated that metal curcumin 
complexes were roughly three times as effective as curcumin.89 Their studies 
have been corroborating the importance of curcumin's free phenolic OH groups 
for scavenging oxidants and correlating with reduced cytotoxic potential.89 
Dutta and co-workers have examined two stoichiometrically different 
copper(ll) complexes of curcumin for their superoxide dismutase (SOD) activity, 
free radical-scavenging ability, and antioxidant potential in anticipation of 
developing SOD mimics.91 EPR was used to confirm the structures of the 1:1 and 
1:2 complexes as distorted orthorhombic and symmetric square planar, 
respectively. The 1:1 Cu(ll)-curcumin complex was ten times more potent as the 
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SOD mimic than the 1:2 Cu(ll)-curcumin complex. Similarly the rate constant for 
the scavenging of superoxide radical of the 1:1 complex has been found to be 
seven times higher than that of the 1:2 Cu(ll)-curcumin complex. The two Cu(ll) 
complexes show similar electron and hydrogen atom transfer reactions with free 
radicals and produce the phenoxyl radicals similar to those produced from 
curcumin. This may be mainly from the phenolic OH groups of curcumin which 
are intact and unaffected by the chelation with Cu(ll).91,98 The stability of the 
resultant phenoxyl radicals therefore imparts greater ability for curcumin to 
scavenge the oxidizing free radicals. This finally resulted in a much greater ability 
to inhibit free radical-induced lipid peroxidation and the antioxidant activity.98 
It was also concluded that the 1:1 complex would be able to undergo and 
sustain the distortion from square planar geometry to the distorted tetrahedral 
one during its reaction with superoxide radical.91 This allows for the compound to 
remain intact and undergo many redox cycles and is as an efficient antioxidant. 
However, the 1:2 complex is planar but rigid, hence it cannot undergo the 
distortions and is a less powerful antioxidant.91 
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H3CCOOx 0H 2 
Figure 3.4. Proposed Cu(ll) curcumin complexes studied as superoxide 
dismutase mimics (A = 1:1 Cu(ll) curcumin complex, B = 1:2 Cu(ll) curcumin 
complex) 91 
Saladini and co-workers have been interested in developing iron 
deficiency treating agents " as well as iron overload agents9010° based on 
curcumin. The p-diketone moiety of curcumin demonstrated coordination ability 
toward Fe(lll).101,102 Its main drawback in the clinical use is its low water solubility, 
as mentioned in the previous chapter. In order to overcome this handicap, they 
have synthesized glycosylated curcuminoids.101"103 (Figure 3.5.) These 
compounds add iron chelating ability, increased water solubility and free-radical 
scavenging activity, inhibiting the iron redox cycle.101"103 
0 OH 
H3CO OCH< 





Figure 3.5. Saladini's glycosyl-curcumin 101,102 
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Solution Studies of Curcumin and Metals 
While there is a lack of structural data of metal curcumin, there is literature 
that describes the aqueous speciation of curcumin with Fe(ll/lll).90 The 
thermodynamic data is consistent with curcumin acting as an Fe(lll) chelator, 
which is best evidenced in the calculation of the pM values for both Fe(ll) and 
Fe(lll) at pH = 7.4, 1 uM iron, 10 uM curcumin.90 













































The reduced pM for curcumin as compared to these iron chelators, which 
are typically used to treat iron overload, is related to its reduced denticity 
because curcumin is bidentate and desferrioxamine is hexadentate. However, 
the pM value of curcumin compares favorably to the iron chelator nitrilotriacetic 
acid (NTA) and many other iron chelators. As such it is consistent with chelation 
activity in vivo.54'104 
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Relative to possible roles of metal-binding to biological action of curcumin, 
it is important to study metal complexation in an aqueous solution within 
biologically relevant pH ranges and at a range of stoichiometry appropriate to the 
solubility and bioavailability of curcumin. In 2003, Rojas-Hernandez and co-
workers reported that only 1:1 (M:L) metal complexes of curcumin are seen 
experimentally based on aqueous speciation of 10 uM curcumin and 1 uM Fe(lll) 
or Fe(ll) over the pH range of 5.5 to 10.5.104 Considering the low bioavailability 
of curcumin, it is possible that the concentration of curcumin will be less than the 
concentration of iron in biological media. 
Varying coordination numbers are provided by curcumin, and that 
coordination number can affect whether Fe(lll) is tightly held, which is important 
for its in vivo chelation activity and potential use to treat both iron overload and 
deficiency. Similarly, its coordination number with iron can affect the properties of 
the complex such as whether bound iron can catalyze the Fenton reaction or be 
a SOD mimic.105 Therefore, it is important to examine how curcumin behaves 
with iron in physiologically relevant conditions. 
In this chapter, we present the iron coordination chemistry of curcumin 
and its derivative 4,4'-dimethoxycurcumin in solution characterized by a 
combination of spectrophotometry, EPR, solution magnetic moment and ESI-MS. 
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Results and Discussion 
Chemical Degradation Studies of Curcumin 
A major challenge in using curcumin for treatment of diseases is the poor 
aqueous solubility (~20 ug/mL), which significantly limits its availability in 
biological systems. For the fraction of curcumin that is aqueous soluble, another 
main challenge to widespread clinical application is hydrolytic activity in mildly 
basic solution 64. As pH ~8, curcumin undergoes rapid degradation first by 
hydrolysis, giving trans-6-(4'-hydroxy-3'methoxyphenyl)2,4-dioxo-5-hexenal, 
which is then followed by molecular fragmentation, giving vanillin, ferulic acid, 
and feruloylmethane.64 A number of studies describe increasing the aqueous 
"solubility" of curcumin can be improved by increasing the pH of the solution. 
However, the process actually occurring is the alkaline hydrolysis of curcumin to 
molecules that are more soluble because they contain more polar functional 
groups and have lower molecular weight.106~108 Some of the experiments were 
conducted at high pH (>11). Due to the high rate of degradation at these pH 
values, it is unclear whether curcumin or the degradation products were 
responsible for the observed effects. Therefore, the ability to stabilize curcumin at 
basic pH can address this important issue. 
While examining curcumin and iron in basic solution (including buffer 
solutions), degradation of curcumin was observed. After one hour in basic 





Figure 3.6. Curcumin in 0.01 M PBS solution (pH 7.4) at room temperature for 
60 minutes 
The following experiments were performed to confirm the degradation of 
curcumin and examine the effects of iron in buffered solution. Curcumin (2.0(2) x 
10~5 M) in pH 7.4 PBS solution caused a decrease of the free curcumin 
absorption at 420 nm by ~ 50% over 60 minutes. When iron (2.0(2) x 10~5 M) 
was added into a curcumin solution (2.0(2) x 10~5 M) in same condition as 
curcumin alone, only ~17.5 % decrease of the free curcumin absorption at 420 
nm was observed with a small steady increase of a new iron-curcumin peak at 
540 nm (Figure 3.7). A clear isosbestic point was observed in the stacked 
spectral plots when Fe(lll) was added. This suggests a clean conversion 
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between curcumin and iron-curcumin complex. Therefore, Fe(lll) has an ability to 
stabilize curcumin at pH 7.4 PBS. 
450 550 
Wavelength (nm) 
Figure 3.7. Curcumin and Iron (1:1) complex in 0.01 M PBS solution (pH 7.4) at 
room temperate for 60 minutes 
In order to examine the nature of decomposed curcumin A, 1H NMR study 
of curcumin in pH 7.4 PBS solution was attempted. However, no meaningful 
NMR spectrum was collected due to solubility limits of curcumin in water. 
Therefore, D2O was used with NaOD, instead. Yellow curcumin powders were 
immediately dissolved in D20 with NaOD, giving a dark red color. It was 
proposed by Tonnesen that the condensation products of feruloylmethane might 
be responsible for this color.106 To confirm the previous finding by 1H NMR, 
ferulic acid was added into the NMR tube and compared with a spectrum without 
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additional ferulic acid. (Figure 3.8). There were growing peaks which were 
recognized as ferulic acid. Therefore, it was confirmed that some curcumin in 
basic solution decomposed to ferulic acid monitored by 1H NMR. 
A: Curcumin (in D20 with NaOD) 
_„AJ\A%L I I • * • . . 
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Figure 3.8. NMR spectrum of curcumin (A) and curcumin with additional ferulic 
acid (B) in D20 with NaOD 
There was the appearance of a pair of doublets (6.33 and 7.48 ppm) in the 
aromatic region with J values of 15.8 Hz for the frans-alkene protons of curcumin 
present. There was an additional doublet at 6.03 ppm with J values of 15.8 Hz for 
the trans-alkene protons of ferulic acid. Although, Roughley and Wong have 
proposed few other decomposed products, only ferulic acid has been identified 
here by the 1H NMR method.64'109 It is quite possible that other products are still 
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in solution, but not detected due to low concentration of the curcumin in D2O 
solution. Also Roughley reported that ferulic acid does not undergo further 
degradation, while feruloylmethane may degrade to vanillin and acetone with 
presence of additional base.109 Therefore it is consistence with our 1H NMR 
spectra. Further evaluation of the degradation of curcumin, and its implications 





ferulic acid feruloylmethane 
Scheme 3.1. Degradation of curcumin in basic solution (proposed by 
Tonnesen)106 
Reduction of Fe(lll) to Fe(ll) by Curcumin Anion 
In the redox studies, two equivalents of base were used to produce the 
anion of curcumin (curcumin2"), at approximately pH 9.78. As mentioned in 
Chapter 2, it has been shown that curcumin has three pKg values at 
approximately 8.38, 9.88, and 10.51 in aqueous solution, corresponding to 
deprotonation of the three hydroxyl groups, therefore, curcumin is fully 




 We are interested in curcumin2" and the anions of base-degraded curcumin 
due to their potential to produce phenoxyl radicals, which may be generated by 
one-electron oxidation followed by proton loss from curcumin phenolic OH 
group.98 It is well-known that phenolate anions can reduce Fe(lll) to Fe(ll) and 
phenoxyl radical.110,111 
Figure 3.9. Anions of curcumin (A = curcumin", B = curcumin2", C = curcumin3") 
EPR and NMR 
A former graduate student in the Planalp group, Dan P. Kennedy, has 
shown that curcumin2" reduces Fe(lll) to Fe(ll) by the Evans' method in 1H NMR 
and by Electron Paramagnetic Resonance (EPR) studies in collaboration with Dr. 
Fadi Bou-Abdallah and Dr. N. Dennis Chasteen at the University of New 
Hampshire. 
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The EPR data suggest that in the presence of base curcumin will reduce 
the oxidation state of Fe(lll) to Fe(ll). EPR showed that the g = 4.3 feature of the 
reaction Fe(lll) + curcumin2" was reduced in intensity as compared to the Fe(lll) -
EDTA standard, which is consistent with either aggregation within the sample or 
reduction of the oxidation state. The aggregation possibility was ruled out by 
running serial dilutions of the sample and plotting the intensity of the g = 4.3 
signal as a function of total Fe(lll) concentration, which resulted in a linear 
relationship. An EPR spectrum is not expected for Fe(ll) species because of the 
even number of unpaired electrons for a high spin (HS) d6 metal in an octahedral 
field.105 
1H NMR was used to confirm if redox chemistry was taking place between 
curcumin and Fe(lll) in order to measure the magnetic susceptibility of various 
mixtures of iron and curcumin. (Table 3.2.) 




1:1 Fe-curcumin no 
NaOD added 
1:1 Fe-curcumin + 
2.00 equiv NaOD 
1:1 Fe-4,4'-DMCU 
+ 2.00 equiv NaOD 















Both methods, EPR and NMR, clearly show that Fe(lll) is being reduced to 




The ferrozine method has been used to examine the extent that curcumin 
and 4,4'-DMCU reduce Fe(lll) in basic solution. The method assays presence of 
Fe(ll) by formation of [Fe(ferrozine)3]4". In 1970, Stookey reported the synthesis 
of ferrozine 112 and pointed out its major advantages, these being the high molar 
absorptivity of the Fe(ll)-ferrozine complex (28,000 Lmor1cm"1), its water 
solubility, and stability over the pH range of 4-9 (Figure 3.10).112 Also this 
method can be used with various cell studies, which may be useful to understand 
behaviors of curcumin both in vivo and in vitro.113-119 
Figure 3.10 [Fe(ferrozine)3]4" complex and ferrozine 
Reaction of Fe(lll) with curcumin2" showed ~ 56 % (in MeOH) and 31.3 % 
(in MeOH/H20 = 1:1 (v/v)) of reduction of Fe(lll) to Fe(ll) almost immediately after 
adding Fe(lll) to curcumin in basic media with 3 eq ferrozine (Table 3.3). The 
reduced Fe(ll) was quantified by addition of ferrozine to the reaction followed by 
spectrophometric measurement of [Fe(ferrozine)3]4" at 562 nm. The reaction 
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appears to occur immediately (less than 5 s). The addition of ferrozine to the 
mixture of Fe(lll) and curcumin in base after one hour did not show additional 
reduction of Fe(lll) to Fe(ll). 
Table 3.3. UV/Vis spectroscopic studies for redox 
Reactions 
Fe(lll) + 1 eq curcumin + 2 eq NaOH + 3 eq Ferrozine 
Fe(lll) + 1 eq curcumin + 3 eq Ferrozine 
Fe(lll) + 3 eq curcumin + 6 eq NaOH + 3 eq Ferrozine 








However, no growth at 562 nm was observed when pH=7.4 PBS solution 
was used as a solvent. Therefore no reduction was observed. In this pH region, it 
is presumed that only the enolic proton is deprotonated, giving curcumin". This 
data support that activity of phenolate is reducing Fe(lll) to Fe(ll). 
Use of ferrozine was carefully monitored since it could change the redox 
potential (Equation 1) and promote reduction of Fe(lll).120 
Fe3+(aqr) + e- - • Fe2+(aq) (1) 
In the control experiments, ferrozine was added into Fe(lll) in solution in order to 
examine if it would promote reduction of Fe(lll) to Fe(ll) in a given period. No 
reduction was observed in the first 30 minutes, but a small reduction (-10%) was 
observed thereafter. Therefore it appeared ferrozine did not affect Fe" formation 
in a given condition (both in MeOH and in MeOH/H20 = 1:1 (v/v)). 
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From previous reports of Fe(lll) and curcumin reactions, binding 
stoichiometries of 1:1,1:2 and 1:3 (M:L) have been suggested.90 Postulating that 
a greater amount of curcumin might increase the reduction of Fe(lll), we 
examined 1:3 metal complexes of curcumin in basic solution. When 1:3 (M:L) 
metal complexes of curcumin with two equivalents of bases per one equivalent 
curcumin (prepared in solution, not isolated complexes) were quantified by 
spectrophometric measurement of [Fe(Ferrozine)3]4" (both in MeOH and in 
MeOH/hbO = 1/1 (v/v)), no additional reduction of Fe(lll) to Fe(ll) was observed, 
relative to the 1:1 (M:L) metal complexes of curcumin that were obtained in 
solution. 
UV/Vis Titration Studies of Curcumin and Derivatives with Fe(lll) 
In order to determine the range of possible stoichiometries for iron 
complexation by curcumin and 4,4'-DMCU, UV-Vis titrations of curcumin and 
4,4'-DMCU with Fe(lll) were carried out in various solvents condition (Table 3.4.) 








Fe(lll) + curcumin + 2 eq NaOH 
Fe(lll) + 4,4'-DMCU + 2 eq NaOH 
Solvents 
MeOH 
MeOH/H20 (v/v =1:1) 




The addition of FeCI3»6H20 (2.0(1) x 10"3 M) in 0.10 M HCI to methanolic 
curcumin (3.0(2) x 10~5 M) caused a steady decrease of the free curcumin 
absorption at 420 nm and the growth of a 440-nm signal, followed by the 
formation of another new signal at 540 nm. (Figure 3.11) All of the bands are 
assigned ion-n* of the phenol ring based on literature.104 A plot of Fe'" vs. 
signal intensity (A.U.) at 540 nm reveals two regions of complexation, the first 
assigned to Fel_3 and, the second to Fel_2 based on the slopes and calculated 
stoichiometries. No clear isosbestic point was observed in the stacked spectral 
plots, which suggests that there is no clean formation of iron-curcumin complex, 
possibly because it consists of Fe(ll) and Fe(lll)-curcumin complexes, and/or of 
complexes with ferulic acid and curcumin. However, the new shifted peak at 440 
nm appeared after addition of 0.5 mol eq Fe(lll) (M:L = 1:2), but did not decrease 
after reaching close to 1 mol eq. of Fe(lll). Possibly, it is replaced by another 
signal that is characteristic of a 1:2 Fe:curcumin complex. A curcumin2" peak at 
420 nm decreased as iron-curcumin complex grew around 540 nm before shifting 
to 440 nm. Degradation of curcumin anions might not be the major contribution of 
decreasing the peak at 420 nm due to relatively short reaction time of titration (~ 
20 minutes) and addition of Fe(lll), which were shown by degradation studies in 
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Figure 3.11. Reaction 1: Titration of curcumin (L) with Fe(lll) in MeOH with 2 
equiv NaOH showing spectral changes including the growth of a new signal at 
540 nm. The inset figure shows the intensity of the 540-nm absorbance versus 
the mole ratio of Fe(lll) to curcumin (M/L). Formation of both 1:3 and 1:2 (M:L) 
metal complexes of curcumin are observed. 
In order to understand the influence of water on the binding and obtain 
insight to the biological environment, the titration described was also conducted 
in aqueous MeOH (MeOH:H20 = 1:1 (v/v)) and in 0.01 M PBS buffer (pH 7.4) as 
solvent. (Table 3.4) 
In aqueous MeOH, similar UV-Vis spectral patterns were observed, where 
a band at 420 nm decreased and a new band appeared at 440 nm at 0.5 mol eq 
of Fe(lll). The band at 440 nm is assigned to n - n* of the phenol ring on Fe-
curcumin complex.104 Unlike the reaction in MeOH alone, the band at 440 nm 
also decreased with the addition of Fe(lll). A new absorption band at 540 nm was 
formed from Fe(lll)-complexes as previously observed. Beyond 0.33 mol eq. of 
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Fe(lll), the band at 540 nm remained unchanged. These data are consistent with 
the formation of 1:3 and 1:2 (M:L) metal complexes of curcumin. 
When pH = 7.4 PBS solution was used, no new UV-Vis bands were 
observed, which might indicate no binding of iron in this solution. Therefore no 
binding stoichiometries were determined. However, the degradation of curcumin 
was observed (Figure 3.6). 
4.4'-DMCU 
The addition of methanolic FeCI3«6H20 (2.0(1) x 10~3 M) to methanolic 
4,4'-DMCU (3.0(2) x 10~5 M) caused a steady decrease of the free 4,4'-DMCU 
absorption at 426 nm and the growth of a 450-nm signal, followed by the 
formation of a another new signal at 540 nm. All of the bands are assigned to n 
- n* of the phenol ring based on literature.104 A plot of Fe(lll) vs. signal intensity 
(A.U.) at 540 nm reveals two regions of complexation, the first assigned to Fel_3 
and the second to FeL2 based on the slopes and calculated stoichiometries. No 
clear isosbestic point was observed in the stacked spectral plots. However, the 
new shifted peak at 440 nm did not decrease after reaching close to 1 mol eq. of 
Fe(lll). (Figure 3.12). 
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Figure 3.12. Reaction 4: Titration of 4,4'-DMCU (L) with Fe(lll) in MeOH 
showing spectral changes including the growth of a new signal at 540 nm. The 
inset figure shows the intensity of the 540-nm absorbance versus the mole ratio 
of Fe(lll) to curcumin (M/L). Formation of both 1:3 and 1:2 (M:L) metal 
complexes of curcumin are observed. 
ESI-MS Studies 
ESI-MS allows the acquisition of mass spectra directly from solution 
samples, thus analyzing all the equilibrium species in their starting 
environment.30 ESI's soft ionization character minimizes fragmentation, leaving 
mostly unaltered the species existing in the solution. The stoichiometry of these 
species can be determined directly from their m/z(mass/charge) values.30 
Another favorable property of ESI-MS is its low detection level, as 
concentration values down to 10"6 M can be investigated,30 which is particularly 
useful to examine curcumin and its complexes due to their low solubility. Unlike 
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NMR, ESI-MS is able to analyze ionic species in solution irrespective of the 
nuclear spin of constituent atoms. Therefore, ESI-MS experiments were carried 
out in order to determine more accurately the stoichiometry of the complexes 
formed between curcumin and iron. 



















MeOH/H20 = 1:1 
MeOH 
Solutions containing iron and curcumin were prepared over a range of 
sample concentrations from 10"4 to 10"6 M in methanol. There was no evidence of 
any solvent species coordinated to any metal complexes (e.g. H20, OH", MeOH). 
Iron-bound substances are easily recognized due to the characteristic isotopic 
pattern of iron. (Table 3.6)121 
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Figure 3.13. An example of the electrospray mass spectrum (Reaction 4): 
[Fe'"(curcumin)2]+ - a cluster of peaks at m/e = 790.1 with a simulated peak of 




Figure 3.14. Proposed gas-phase complex between curcumin and iron based on 
ESI-MS. 
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The electrospray mass spectra of curcumin in presence or absence of 
either NaOH or Fe(lll) were obtained in methanol solution (Table 3.5). 
Regardless, various amounts of curcumin, NaOH and iron, the highest intensity 
(base peak) always occurred at a cluster of peaks at m/e = 790.1, corresponding 
to "[Fe'"(curcumin)2]+" (Figure 3.15). However, when no base was used, the 
spectrum is very clean. When base is present, either the base promoted 
degradation of curcumin or the radical-induced degradation by formation of 
phenoxyl radical and Fe(lll) may lead to many peaks. (Figure 3.16) 
(+) ESI-MS of Fe(lll) + curcumin in MeOH (no base added) 
JC280-2#1-191 RT: 0.02-5.01 AV: 191 NL: 8.39E5 
T: + p Full ms [ 150.00-1500.00) 
I 
177.1 227.5^3,
 3 ; 8 1 « ^ - ' " ° j » ° 566.1 632.6 636.5 7 6 1 , 843.9 883.1 | 1058,7 10676 1157.1 1211.0 1 2 7 | ' " 1377J 1423.5 ) f l M 
200 300 400 500 
S„,;^"„„:,^;:„:'.;;y i. 
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Figure 3.15. An example of the electrospray mass spectrum (Reaction 2): 
[Fe'"(curcumin)2]+ - a cluster of peaks at m/e = 790.1 
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(+) ESI-MS of Fe(lll) + curcumin in MeOH (2 eq base added) 
JC282-1#1-64 RT: 0.01-2.03 AV: 64 NL: 1,53E6 
T; + p Full ms [ 215.00-2000.00) 
lOOq 
355.2 44a 2 7 
285.1 I ^ ? ' 426.4 602.9 696.7 ' 
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Figure 3.16. An example of the electrospray mass spectrum (Reaction 1): 
[Fe'"(curcumin)2]+ - a cluster of peaks at m/e = 790.1 
When water was used as a co-solvent, a spectrum had poor resolution 
which was caused by low solubility. Therefore, free curcumin as well as 
[Fe'"(curcumin)2]+ were observed along with various unidentified fragments. 
(Figure 3.17) 
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(+) ESI-MS of Fe(lll) + curcumin in 1/1 (v/v), MeOH/Water (no base 
JC281-1 #1-182 RT: 0.02-5.00 AV:182 NL:3.73E4 
T: + pms[ 150.00-1500,00J 
391.1 
added) 
Figure 3.17. An example of the electrospray mass spectrum (Reaction 3): 
[Fe'"(curcumin)2]+ - a cluster of peaks at m/e = 790.1 
72 
CONCLUSION 
The reduction of Fe(lll) to Fe(ll) by curcumin2" was observed using a 
chemical method, trapping Fe(ll) using ferrozine in solution. 56 % (in MeOH) and 
31.3 % (in MeOH/H20 = 1:1 (v/v)) of Fe(lll) were reduced to Fe(ll). Formation of 
1:1,1:2, and 1:3 (M:L) species were observed in given solvent systems. 
Additional curcumin2" did not promote the reduction of Fe(lll) to Fe(ll). In the case 
of 4,4'-DMCU, no reduction of Fe(lll) to Fe(ll) was observed. 
UV-Vis titration spectra of curcumin did not have clear isosbestic points. 
Reduction of Fe(lll) to Fe(ll) may have contributed to these complications, 
affording many Fe(lll) and Fe(ll)-curcumin complexes. And degradation of 
curcumin might also contribute to the complications. While UV-Vis titration 
spectra suggest various possible species in solution, ESI-MS does not support 
this, suggesting only a Fe(lll)-curcumin (1:2) complex. When a pH 7.4 PBS 
solution was used to examine iron and curcumin, no redox was observed. 
Although curcumin was degraded in pH 7.4 PBS solution, it was degraded 
much less when iron was present. This suggests that complexation between iron 
and curcumin inhibits the degradation of curcumin in pH 7.4 PBS solution. Based 
on 1H NMR data, formation of ferulic acid was observed in its process of 
degradation in D2O with NaOD. 
In summary, curcumin acts both as an antioxidant enzyme inducer and 
cellular iron chelator. Also curcumin is Fe(lll) chelator and does form different 
order complexes with iron (i.e. 1:2 and 1:3 Fe-curcumin species). 4,4'-DMCU 
which has no phenolic group did not participate in redox chemistry with iron in 
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methanolic solution. Lastly, degradation of curcumin was decreased with iron 
present. 
Further biological studies are needed to understand how curcumin 
compares with 4,4'-DMCU where no phenols are present. Also, degradation 
products of curcumin should be considered when both chemical and biological 
properties of curcumin are evaluated. Gas chromatography-mass spectrometry 
(GC-MS), High performance liquid chromatography-mass spectrometry (HPLC-
MS), or ESI-MS could be a very important tool in order to understand both 
degraded products and coordination complexes. Iron-curcumin complex should 







1H and 13C NMR spectra were recorded on a Varian Mercury 400 MHz NMR 
spectrometer or a Varian INOVA 500 MHz NMR spectrometer with an inverse 
probe. Spectra were measured in Choloroform-di (CDCI3), deuterated water 
(D20), Methanol-d4 (MeOD-d4), dimethylsulfoxide-d6 (DMSO-d6) with tetramethyl 
silane (TMS) as an internal standard. Chemical shifts are reported in parts per 
million (ppm) relative to the internal standard. 
Melting Points (mp) were recorded on a Thomas Hoover capillary melting point 
apparatus and are uncorrected. 
Infrared Spectra (IR) were run on a Thermo Nicolet Avatar 380 FT-IR 
spectrometer and absorptions are reported in wavenumbers (cm'1). 
UV/Vis/NIR solution electronic spectra were measured using a Varian Cary 
50-Bio UV/Vis spectrometer with 1 ml_ quartz cuvettes (1 cm path length). 
Deconvolutions of electronic absorption spectra were performed using Microcal 
Origin 6.0 software. 
Electrospray Ionization Mass Spectra (ESI-MS) was obtained on a 
Thermoquest LCQ mass spectrometer at the University of New Hampshire. ESI-
MS in the positive ion detection mode were obtained with a Finnegan LCQ 
75 
Classic instrument with dual optical Paul traps and Picoview nanosource. The 
analyses employed a flow rate of 2 to 3 ul/min, a spray voltage at 1.5 - 2 kV, and 
a capillary voltage of 10 V at capillary temperature of 200 °C. Confirmation of all 
major species in this ESI-MS study was aided by comparison of the observed 
and predicted isotope distribution patterns from the program developed by 
Scientific Instrument Services (http://www.sisweb.com/cgi-bin/mass10.pl, 
accessed April, 2008). 
X-Ray Crystallography experiments were carried out by Dr. Arnold Rheingold 
and Dr. Antonio DiPasqulae at the University of California San Diego 
crystallography facility. Details about each experiment are reported in APPENDIX 
B. 
Elemental Analysis (CHN) was performed by Atlantic Microlabs (Atlanta, 
Georgia). 
Magnetic Moments were measured by Evan's NMR method using residual 
CD2HCN, CD2HSOCD3 or t-butanol (v/v) as indicator in both the sample and 
closed capillary. All magnetic moments are reported in Bohr Magneton (BM). 
Solvents 
The following solvents were freshly obtained from the automatic still: diethyl ether 
(Et20), dichlorometane (CH2CI2), methanol (MeOH), acetonitrile (MeCN), 
dimethylformamide (DMF), Et20 was also used immediately after distillation from 
Na. Water was deionized by reverse-osmosis and by anion and cation exchange 
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(E-pure model D4641, Barnstead). All deuterated solvents for NMR analysis 
were purchased from Cambridge Isotope Laboratories and kept in a dessicator. 
Reagents 
All chemicals were of research grade or of spectro-quality grade and were 
generally obtained from commercial sources and used without further purification 
except for those described as follows. 
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Chapter 1 Experimental 
The following abbreviations were used to assign NMR spectra: s, singlet; d, 
doublet; dd, doublet of doublets; q, quartet; brs, broad singlet; brd, broad 
doublet; br t, broad triplet. 
Tach-3-MeOpyr (L|). 
The ligand was prepared by Dr. Matin Brechbiel et al. at the NIH and kindly 
donated. 1H NMR (300 MHz, d6-DMSO, 25°C):5 = 8.07, 7.35, 7.23 (dd, dd, dd, 3 
H, 3-MeOC5H3N), 3.80 (m, 5 H, 3-CH30py, MeOpyCH2N), 2.42 (t, 1 H, 
cyclohexyl methane /-/), 2.20 (d, 1 H, equatorial cyclohexyl methylene /-/), 0.85 
(dd, 1 H, axial cyclohexyl methylene H). 13C NMR (d6-DMSO) 6 153.5, 149.1, 
140.6, 122.7, 116.9, 55.4, 54.2, 47.0, 40.0. 
[Ni(tach-3-MeOpyr)](CI04)2 (1a). 
A solution of Ni(CI04)2-6H20 (0.0165 g, 4.512 x 10"5 mol) in MeOH (0.5 mL) was 
mixed with a pale yellow/brown solution of tach-3-MeOpyr (0.0100 g, 2.03 x 10"5 
mol) in MeOH (0.5 mL). A light pink/purple color was observed. Diffusion of Et20 
into the solution overnight gave clusters of light pink needles. The precipitate was 
recrystalized with MeCN by Et20 diffusion. The product was isolated, washed 
with Et20, and dried under reduced pressure giving pink needles (0.0111 g, 
72.5 %). 
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[Fe(tach-3-MeOpyr)](FeCI4)*Et20 (1 b). 
A pale green solution of FeCI2«4H20 (0.0101 g, 5.10 x 10"5mol) in MeOH (1 mL) 
was added to a pale yellow solution of tach-3-Mepyr (0.0174 g, 3.53 x 10"5 mol) in 
MeOH (1 mL) producing a brown-yellow solution. MeOH (1 mL) producing a 
brown-red solution. Diffusion of Et20 into the solution overnight gave clusters of 
red plates. The precipitate was recrystalized with MeOH (0.75 mL) and MeCN 
(0.75 mL) by Et20 diffusion overnight, producing clusters of carmine red plates 
suitable for X-ray crystallography. Product was isolated and dried under reduced 
pressure affording deep red needles. Analytically calculated for 
C27H39Cl2FeN601.5(597.19): C, 54.25; H, 6.58; N, 14.07. Found: C, 54.17; H, 
6.22; N, 13.76. 
[Fe(tach-3-MeOpyr)]CI2 (1c). 
A pale green solution of FeCI2«4H20 (0.00700 g, 3.53x10"5 mol) in MeOH (1 ml) 
was added to a pale yellow solution of tach-3-Mepyr (0.0155 g, 3.48x10"5 mol) in 
MeOH (1 ml) producing a brown-yellow solution. Et20 (2 ml) was added and the 
solution allowed to stand for 48 hrs at 10°C producing clusters of carmine red 
needles suitable for X-ray crystallography. Product was isolated and dried under 
reduced pressure affording deep red needles. 1H NMR (400 MHz, d6-DMSO, 
25 °C): 5 = D7.59, 7.15, 6.91 (d, dd, d, 3H, 3-Me-C5H3N); 5.29 (brt, 1H, NH-
CH2); 4.23, 4.02 (dd, dd, 2H, (NH-CHa-py), diastereotopic); 2.95 (brs, 1H, 
cyclohexyl methine H); 2.37 (s, 3H, (C/-/3-py)); 2.12 (br d, 1H, equatorial 
cyclohexyl methylene H); 1.84 (br d, 1H, axial cyclohexyl methylene H). 
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[Cu(tach-3-MeOpyr)](CI04)2 (1d). 
A solution of Cu(CI04)2-6H20 (0.0161 g, 4.35 x 10"5 mol) in MeOH (0.5 ml_) was 
mixed with a pale yellow/brown solution of tach-3-MeOpyr (0.0149 g, 3.02 x 10"5 
mol) in MeOH (0.5 ml_). A blue precipitate was observed immediately. Diffusion 
of Et.20 into the solution overnight gave clusters of blue color needles. The 
precipitate was recrystallized with MeCN by Et2<D diffusion. The product was 
isolated, washed with Et20, and dried under reduced pressure giving blue 
needles (0.0140 g, 61 %). 
[Zn(tach-3-MeOpyr)](CI04)2 (1e). 
A solution of Zn(CI04)2-6H20 (0.0121 g, 3.25 x 10'5 mol) in MeOH (0.5 mL) was 
mixed with a pale yellow/brown solution of tach-3-MeOpyr (0.0127g, 2.578 x 10'5 
mol) in MeOH (0.5 mL). No color change was observed. Diffusion of Et20 into the 
solution overnight gave clusters of colorless needles. The precipitate was 
recystalized with MeCN by Et20 diffusion. The product was isolated, washed with 
Et20 and dried under reduced pressure giving white needles (0.0121 g, 62%) 1H 
NMR (300 MHz, d6-DMSO, 25°C): 5 = 7.73, 7.49 (dd, m, 3 H, 3-MeOC5H3N), 
4.38 (t, 1 H, A/HCH2), 4.08, 3.80 (dd, dd, 2 H, MeOpyCH2N, diastereotopic), 3.92 
(s, 3 H, CH3OC5H3N), 3.28 (s, 1 H, cyclohexyl methane H), 2.26 (d, 1 H, 
equatorial cyclohexyl methylene H), 1.84 (d, 1 H, axial cyclohexyl methylene /-/). 
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Solution-phase complexation 
Solution complexation studies for Ni(ll) and Cu(ll) were carried out as described 
below and the solutions obtained were studied by UV-Vis. The yields of the 
solution complexation were not determined. 
Ni(ll) Complexation: Aqueous NiCfe (60 uL, 0.1 M) was added to aqueous tach-
3-MeOpyr (60 uL, 0.0997M) producing a clear violet solution, which turned into a 
clear pink solution. Water (880 uL) was added to the reaction to produce a pink 
solution for UV/Vis spectroscopic analysis. 
Cu(ll) Complexation: Aqueous CuCI2 (20 uL, 0.1M) was added to aqueous tach-
3-MeOpyr (20 uL, 0.1 M), producing a blue solution that was diluted with water to 
produce a blue solution for UV/Vis spectroscopic analysis. 
ESI-MS studies 
[Zn(tach-3-MeOpyr)](CI04)2, [Cu(tach-3-MeOpyr)](CI04)2, [Ni(tach-3-
MeOpyr)](CI04)2, and [Fe(tach-3-MeOpyr)]Cl2 were dissolved in a HPLC-grade 
MeOH solution to a concentration of 10"4 to 10"5 M by successive dilution. In the 
case of [Fe(tach-3-MeOhpyr)]Cl2, imine species are observed due to oxidative-
hydrogenation in the presence of air with traces of unoxidized and monoamine. 
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Chapter 2 Experimental 
The following curcuminoids were prepared with modified synthetic methods of 
Pabon. 80 
4,4'-dimethoxycurcumin(DMCU) (2) 
2,4-pentanedione (acacH, 1.000 g , 1.03 ml_, 10 mmol) and 15 mL of EtOAc and 
B203 (0.5000 g, 7.00 mmol) were added into 100 mL RBF equipped with a Teflon 
coated stir bar. The flask was then fit with a Claisen adapter equipped with a 
rubber septum and N2 inlet. The head space was purged with N2 for 10 minutes 
and then the RBF was immersed in a thermostated bath at 40 °C for 30 minutes. 
A milky white suspension formed in the RBF. A solution of 3,4-
dimethoxybenzaldehyde (3.290 g, 20.0 mmol) dissolved in 5 mL of EtOAc was 
added into the RBF, followed by neat B(OiPr)3 (3.76 g, 4.61 mL, 20.0 mmol) via a 
glass syringe. The resulting homogeneous orange colored solution was stirred an 
additional 30 minutes at 40 °C. To the solution was then added triethylamine 
(887 mg, 1.28 mL, 15.0 mmol) dissolved in 10 mL of EtOAc. After 15 minutes the 
solution developed a rich red color. After stirring for 17 hours at 40 °C was raised 
to 60 °C and the reaction mixture was added 1.5 mL of concentrated HCI and 8.5 
mL of H2O. After 1 hour the resulting biphasic mixture was allowed to cool to RT 
followed by isolation of the orange layer. The aqueous layer was extracted with 
additional portions of EtOAc (3x10 mL) and the combined organic fractions 
were washed with saturated brine and dried over excess anhydrous MgS04. The 
mixture was filtered via gravity through paper and the solvent removed under 
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vacuum leaving 3.290 g (83% crude yield) of a red/orange solid. The crude 
mixture was chromatographed on silica with 1:1 Hexanes:Ethyl Acetate (v/v) and 
the fractions that contained the compound with Rf=15/40 were pooled and 
brought to dryness. The resulting orange powder was the desired compound and 
proved to be spectroscopically pure, leaving 2.970 g (74.8% yield) of orange 
solid. 1H-NMR(CDCI3): 16.04 (1H, s, enol H's); 7.60 (2H, J=16.0Hz, alkene H's); 
7.14 (2H, dd, Ji=2.0Hz, J2=8.4Hz, aromatic H's); 7.08 (2H, d, J=15.6Hz, alkene 
H's); 5.82 (1H, s, methane H); 3.94 (6H, s, methoxy H's); 3.92 (6H, s, methoxy 
H's). 13C-NMR (CDCI3): 183.5, 151.3, 149.4, 140.6, 128.3, 122.9, 122.2, 111.3, 
109.9, 101.5, 56.2, 56.1 ppm. ESI-MS(in MeOH) = 419.2 (Na+ + 4,4'-DMCU) and 
397.3 (H+ + 4,4'-DMCU) 
Curcumin (3). 
2,4-pentanedione (acacH, 1.000 g , 1.03 ml_, 10 mmol) and 15 mL of EtOAc and 
B203 (0.5000 g, 7.00 mmol) were added into 100 mL RBF equipped with a Teflon 
coated stir bar. The flask was then fit with a Claisen adapter equipped with a 
rubber septum and N2 inlet. The head space was purged with N2 for 10 minutes 
and then the RBF was immersed in a thermostated bath at 40 °C for 30 minutes. 
A milky white suspension formed in the RBF. A solution of vanillin (3.050 g, 20.0 
mmol) dissolved in 14 mL of EtOAc was added into the RBF, followed by neat 
B(OiPr)3 (3.760 g, 4.61 mL, 20.0 mmol) via a glass syringe. The resulting 
homogeneous orange colored solution was stirred an additional 30 minutes at 
40 °C. To the solution was then added triethylamine (887 mg, 1.28 mL, 15.0 
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mmol) dissolved in 10 mL of EtOAc. After 25 minutes the solution developed a 
rich red color from yellow, orange, and dark orange. After stirring for 19 hours at 
40 °C was raised to 60 °C and the reaction mixture was added 1.5 mL of 
concentrated HCI and 8.5 mL of H2O. After 1 hour the resulting biphasic mixture 
was allowed to cool to RT followed by isolation of the orange layer. The aqueous 
layer was extracted with additional portions of EtOAc (3x10 mL) and the 
combined organic fractions were washed with saturated brine and dried over 
excess anhydrous MgS04. The mixture was filtered via gravity through paper and 
the solvent removed under vacuum leaving 3.300 g (89.5% crude yield) of a 
red/orange solid. The crude mixture was chromatographed on silica with 1.1:1 
Hexanes: Ethyl Acetate (v/v) and the fractions that contained the compound with 
Rf=0.27 were pooled and brought to dryness. The resulting orange powder was 
the desired compound and proved to be spectroscopically pure, leaving 2.920 g 
(79.3% yield) of orange solid. 1H-NMR(d-DMSO): 16.04 (1H, s, enol H's); 9.65 
(2H, phenol H), 7.55 (2H, d, J=16.0Hz, alkene H's); 7.32 (2H, d, aromatic H); 
7.15 (2H, dd, J1=2.0Hz, J2=8.4Hz, aromatic H's); 6.82 (2H, d, aromatic H); 6.74 
(2H, d, J=15.6Hz, alkene H's); 6.06 (1H, s, methane H); 3.84 (6H, s, methoxy 
H's). 13C-NMR (d-DMSO): 183.9, 150.0, 148.7, 141.4, 127.0, 123.8, 121.8, 116.4, 
112.0, 101.5, 56.4 ppm. ESI-MS(in MeOH) = 419.2 (Na+ + Curcumin) and 397.3 
(H++ Curcumin) 
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2,4-dimethoxycurcumin (2,4-DMCU) (4). 
Method 1: 
2,4-pentanedione (acacH, 1.000 g , 1.03 ml_, 10 mmol) and 15 mL of EtOAc and 
B203 (0.5000 g, 7.00 mmol) were added into 100 mL RBF equipped with a Teflon 
coated stir bar. The flask was then fit with a Claisen adapter equipped with a 
rubber septum and N2 inlet. The head space was purged with N2 for 10 minutes 
and then the RBF was immersed in a thermostated bath at 75 °C for 30 minutes. 
A milky white suspension formed in the RBF. A solution of 2,4-
dimethoxybenzaldehyde (3.450 g, 20.0 mmol) dissolved in 15 mL of EtOAc was 
added into the RBF, followed by neat B(OiPr)3 (3.760 g, 4.61 mL, 20.0 mmol) via 
a glass syringe. The resulting homogeneous orange colored solution was stirred 
an additional 30 minutes at 40 °C. To the solution was then added piperidine 
(1.48 mL, 15.0 mmol) dissolved in 10 mL of EtOAc. After 15 minutes the solution 
developed a rich red color. After stirring for 1 hour at 100 °C, temperature was 
lowered to 60 °C and the reaction mixture was added 1.5 mL of concentrated HCI 
and 8.5 mL of H2O. After 30 minutes the resulting biphasic mixture was allowed 
to cool to RT followed by isolation of the orange layer. The aqueous layer was 
extracted with additional portions of EtOAc (3x10 mL) and the combined organic 
fractions were washed with saturated brine and dried over excess anhydrous 
MgS04. The mixture was filtered via gravity through paper and the solvent 
removed under vacuum leaving 3.610 g (90% crude yield) of a red/orange solid. 
The crude mixture was chromatographed on silica with 1:2 Hexanes:Ethyl 
Acetate (v/v) and the fractions that contained the compound with Rf=12/30 were 
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pooled and brought to dryness. The resulting orange powder was the desired 
compound and proved to be spectroscopically pure, leaving 2.873 g (72.5% yield) 
of orange solid. 
Method 2: 
2,4-pentanedione (acacH, 1.00 g , 1.03 ml_, 10 mmol) and 15 mL of EtOAc and 
B203 (0.5000 g, 7.00 mmol) were added into 100 mL RBF equipped with a Teflon 
coated stir bar. The flask was then fit with a Claisen adapter equipped with a 
rubber septum and N2 inlet. The head space was purged with N2 for 10 minutes 
and then the RBF was immersed in a thermostated bath at 40 °C for 30 minutes. 
A milky white suspension formed in the RBF. A solution of 2,4-
dimethoxybenzaldehyde (3.450 g, 20.0 mmol) dissolved in 5 mL of EtOAc was 
added into the RBF, followed by neat B(OiPr)3 (3.760 g, 4.61 mL, 20.0 mmol) via 
a glass syringe. The resulting homogeneous orange colored solution was stirred 
an additional 30 minutes at 40 °C. To the solution was then added triethylamine 
(887 mg, 1.28 mL, 15.0 mmol) dissolved in 10 mL of EtOAc. After 15 minutes the 
solution developed a rich red color. After stirring for 18 hours at 40 °C was raised 
to 60 °C and the reaction mixture was added 1.5 mL of concentrated HCI and 8.5 
mL of H2O. After 1 hour the resulting biphasic mixture was allowed to cool to RT 
followed by isolation of the orange layer. The aqueous layer was extracted with 
additional portions of EtOAc (3x10 mL) and the combined organic fractions 
were washed with saturated brine and dried over excess anhydrous MgS04. The 
mixture was filtered via gravity through paper and the solvent removed under 
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vacuum leaving 3.540 g (89.1% crude yield) of a red/orange solid. The crude 
mixture was chromatographed on silica with 1:1 Hexanes:Ethyl Acetate (v/v) and 
the fractions that contained the compound with Rf=12/30 were pooled and 
brought to dryness. The resulting orange powder was the desired compound and 
proved to be spectroscopically pure, leaving 0.827 g (20.9% yield) of orange 
solid. 
1H-NMR(CDCI3): 16.04 (1H, s, enol H's); 7.88 (2H, J=15.9Hz, alkene H's); 7.48 
(2H, d, J=8.5Hz, aromatic H's); 6.61 (2H, d, J=15.9Hz, alkene H's); 6.52 (2H, dd, 
J1=2.4Hz, J2=8.5Hz, aromatic H's); 6.46 (2H, d, J=2.4Hz, aromatic H's); 5.80 (1H, 
s, methane H); 3.89 (6H, s, methoxy H's); 3.85 (6H, s, methoxy H's). 13C-NMR 
(CDCI3): 182.8, 161.6, 158.8, 134.4, 129.1, 121.4, 116.3, 104.4, 100.1, 97.4, 54.5 
ppm. ESI-MS(in MeOH) = 419.2 (Na+ + 2,4'-DMCU) and 397.3 (H++ 2,4'-DMCU) 
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Chapter 3 Experimental 
General Method 
All titrations were monitored using Varian Cary 50 Bio over the range of 1000 nm 
to 250 nm at 23 °C. The UV/Vis spectra were recorded in (name of the software) 
and analyzed further by Microsoft Office Excel 2007. The blanks were prepared 
according to solvents compositions without ligands, metals, and/or base. 
UV/Vis spectroscopic studies for degradation of curcumin 
Stock solutions of curcumin and FeCl3.6H20 were dissolved in a HPLC-grade 
MeOH solution and 0.1 M HCI solution, respectively. UV/Vis spectra were 
recorded on a Cary 50 spectrometer at 23 °C. The experiment was performed by 
addition of 10 uL of metal ion solution (2 mM stock solution, freshly prepared) to 
the ligand solution in a quartz cuvette (10 uL, from 2 mM stock solution in MeOH) 
in 1 mL of 0.1 M PBS pH 7.4. This experiment was compared with the ligand 
solution in a quartz cuvette (10 uL, from 2 mM stock solution in MeOH) in 1 mL of 
0.1MPBSpH7.4. 
UV/Vis spectroscopic studies for redox 
Stock solutions of curcumin, 4,4'-DMCU, and NaOH were prepared in 
concentrations of 2 mM on HPLC-graded MeOH. Stock solution of Ferrozine 
was prepared in concentration of 2 mM on H20. Stock solution of FeCI3.6H20 
was prepared in concentrations of 2 mM on 0.1 M HCI solution to prevent 
formation of metal hydroxides. UV/Vis spectra were recorded on a Cary 50 
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spectrometer at 23 °C. The experiments were performed by addition of 10 uL of 
metal ion solution (2 mM stock solution, freshly prepared) to the same 1 ml_ 
ligand solution in a quartz cuvette in MeOH, MeOH/H20 (v/v = 1:1), or 0.1 M PBS 
pH 7.4. The ligand solution was composed of 10 uL, from 2 mM stock solution in 
MeOH, 20 uL of NaOH, from 2 mM stock solution in MeOH, 30 uL of Ferrozine, 
from 2 mM stock solution in H20 due to its solubility limit in MeOH. 
UV/Vis spectroscopic titration studies 
Stock solutions of curcumin, 4,4'-DMCU, and NaOH were prepared in 
concentrations of 2 mM on HPLC-graded MeOH. Stock solutions of FeCl3.6H20, 
Cu(CI04)2.6H20 were prepared in concentrations of 3 mM on 0.1 M HCI solution 
to prevent formation of metal hydroxides. The titration between ligands and metal 
ions were performed by sequential additions of 0.5 - 1 uL of metal ion solution (3 
mM stock solution, freshly prepared) to a solution of ligand in a quartz cuvette. 
No signs of precipitation were observed during the titrations. The ligand solution 
was composed of 15 uL, from 2 mM stock solution in MeOH, 30 uL of NaOH, 
from 2 mM stock solution in MeOH. All titrations were preformed in MeOH, 
MeOH/H20 (v/v = 1:1), or 0.1 M PBS pH 7.4. The total volume varied from initially 




Stock solutions of curcumin and FeCI3.6H20 were dissolved in a HPLC-grade 
MeOH solution. 50 uL curcumin stock solution (4.0 x 10~4 M) was mixed with 100 
uL NaOH stock solution (4.0 x 10"4 M), followed by 50 uL Fe(lll) stock solution 
(4.0 x 10"4 M). After shaking the solution, this pale orange color solution was 
diluted to a concentration of 10"4 to 10"5 M. No precipitates were observed during 
and after the experiments. 
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Crystal dimensions [mm3] 
Density 
Absorption coefficient [mm"1] 
Refl. Collected/unique 
Theta range [°] 
Parameters 
Goodness of Fit 
Final R indices 
























R = 0.0823 

























R = 0.0413 
Rw = 0.0746 
0.569 
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